Atomoxetine: Treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition

Christopher J Kratochvil, Martin J. Harrington, William J. Burke, Brigette S. Vaughan

Research output: Contribution to journalReview article

Abstract

Atomoxetine (Strattera™), a selective norepinephrine reuptake inhibitor, is the first non-stimulant to be approved for treating attention-deficit/hyperactivity disorder (ADHD). It is the only medication that has received FDA approval for use in adults as well as children with this condition. The results of 9 clinical trials of atomoxetine, including a number of double-blind, placebo-controlled multicenter studies, have demonstrated its high degree of efficacy in controlling the symptoms of ADHD, and favorable patient tolerability, in children, adolescents and adults. While most of the clinical trials employed a twice-a-day dosing schedule, a single daily dose has been shown to be equally efficacious and safe. Transient gastrointestinal side effects were most frequently reported, which in most cases did not lead to discontinuation of atomoxetine therapy. Additional long-term studies are ongoing; direct comparison trials with stimulant agents, and evaluations of atomoxetine in ADHD patients with co-morbid conditions such as substance abuse, depression, anxiety and tics, are warranted to explore the potential for further expanding the use of this novel medication.

Original languageEnglish (US)
Pages (from-to)239-250
Number of pages12
JournalToday's Therapeutic Trends
Volume21
Issue number3
StatePublished - Sep 1 2003

Fingerprint

Attention Deficit Disorder with Hyperactivity
Norepinephrine
Clinical Trials
Therapeutics
Tics
Multicenter Studies
Substance-Related Disorders
Appointments and Schedules
Anxiety
Placebos
Atomoxetine Hydrochloride
Inhibition (Psychology)
Depression

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Atomoxetine : Treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition. / Kratochvil, Christopher J; Harrington, Martin J.; Burke, William J.; Vaughan, Brigette S.

In: Today's Therapeutic Trends, Vol. 21, No. 3, 01.09.2003, p. 239-250.

Research output: Contribution to journalReview article

@article{2263bba1389b4fdf95623e1d069582ae,
title = "Atomoxetine: Treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition",
abstract = "Atomoxetine (Strattera™), a selective norepinephrine reuptake inhibitor, is the first non-stimulant to be approved for treating attention-deficit/hyperactivity disorder (ADHD). It is the only medication that has received FDA approval for use in adults as well as children with this condition. The results of 9 clinical trials of atomoxetine, including a number of double-blind, placebo-controlled multicenter studies, have demonstrated its high degree of efficacy in controlling the symptoms of ADHD, and favorable patient tolerability, in children, adolescents and adults. While most of the clinical trials employed a twice-a-day dosing schedule, a single daily dose has been shown to be equally efficacious and safe. Transient gastrointestinal side effects were most frequently reported, which in most cases did not lead to discontinuation of atomoxetine therapy. Additional long-term studies are ongoing; direct comparison trials with stimulant agents, and evaluations of atomoxetine in ADHD patients with co-morbid conditions such as substance abuse, depression, anxiety and tics, are warranted to explore the potential for further expanding the use of this novel medication.",
author = "Kratochvil, {Christopher J} and Harrington, {Martin J.} and Burke, {William J.} and Vaughan, {Brigette S.}",
year = "2003",
month = "9",
day = "1",
language = "English (US)",
volume = "21",
pages = "239--250",
journal = "Today's Therapeutic Trends",
issn = "0741-2320",
publisher = "Communications Media for Education,Inc",
number = "3",

}

TY - JOUR

T1 - Atomoxetine

T2 - Treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition

AU - Kratochvil, Christopher J

AU - Harrington, Martin J.

AU - Burke, William J.

AU - Vaughan, Brigette S.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Atomoxetine (Strattera™), a selective norepinephrine reuptake inhibitor, is the first non-stimulant to be approved for treating attention-deficit/hyperactivity disorder (ADHD). It is the only medication that has received FDA approval for use in adults as well as children with this condition. The results of 9 clinical trials of atomoxetine, including a number of double-blind, placebo-controlled multicenter studies, have demonstrated its high degree of efficacy in controlling the symptoms of ADHD, and favorable patient tolerability, in children, adolescents and adults. While most of the clinical trials employed a twice-a-day dosing schedule, a single daily dose has been shown to be equally efficacious and safe. Transient gastrointestinal side effects were most frequently reported, which in most cases did not lead to discontinuation of atomoxetine therapy. Additional long-term studies are ongoing; direct comparison trials with stimulant agents, and evaluations of atomoxetine in ADHD patients with co-morbid conditions such as substance abuse, depression, anxiety and tics, are warranted to explore the potential for further expanding the use of this novel medication.

AB - Atomoxetine (Strattera™), a selective norepinephrine reuptake inhibitor, is the first non-stimulant to be approved for treating attention-deficit/hyperactivity disorder (ADHD). It is the only medication that has received FDA approval for use in adults as well as children with this condition. The results of 9 clinical trials of atomoxetine, including a number of double-blind, placebo-controlled multicenter studies, have demonstrated its high degree of efficacy in controlling the symptoms of ADHD, and favorable patient tolerability, in children, adolescents and adults. While most of the clinical trials employed a twice-a-day dosing schedule, a single daily dose has been shown to be equally efficacious and safe. Transient gastrointestinal side effects were most frequently reported, which in most cases did not lead to discontinuation of atomoxetine therapy. Additional long-term studies are ongoing; direct comparison trials with stimulant agents, and evaluations of atomoxetine in ADHD patients with co-morbid conditions such as substance abuse, depression, anxiety and tics, are warranted to explore the potential for further expanding the use of this novel medication.

UR - http://www.scopus.com/inward/record.url?scp=0041734634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041734634&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0041734634

VL - 21

SP - 239

EP - 250

JO - Today's Therapeutic Trends

JF - Today's Therapeutic Trends

SN - 0741-2320

IS - 3

ER -